Bioadhesive Microspheres Market Size, Share and Global Trend By Material (Natural Polymers, Synthetic Polymers), By Route of Drug Delivery (Oral, Nasal, Ocular, Colorectal), By End Users (Hospitals, Clinics, Academic & Research Institutes, Pharmaceutical & Biotechnology Industries), and Regional Forecast, 2024-2032

Bioadhesive microspheres are minute spherical shaped particles, with diametric size ranging from 1µm to 1000 µm. They are usually in powdered form and are used for controlled drug delivery. Bioadhesive microspheres possess the property of prolonged residence time at the target site, thus facilitating a close contact with the absorption surface resulting in better utilization of the drug. Bioadhesive microspheres in recent years are extensively used via oral, ocular, buccal, rectal, nasal, vaginal routes of administration. Using these routes they help in enhancing the bioavailability of the drug. For example, in 2016, according to reports published by the International Journal of Polymer Science, it was demonstrated that bioadhesive microspheres enhanced the oral bioavailability of berberine hydrochloride that was used in the treatment of duodenal and benign gastric ulcers.

Growing advancements in drug delivery systems, increase in the applications of bioadhesive microspheres as a drug carrier, and growing usage of microspheres in clinical research are likely to drive the growth of bioadhesive microspheres market during the forecast period. Additionally, growing investments in research activities by many key players to develop novel microspheres is likely to enhance the growth of bioadhesive microspheres market during the forecast period. For instance, in 2017 according to the International Federation of Pharmaceutical Manufacturers & Association (IFPMA), it was estimated that investments made by research-based pharmaceutical industries on R&D were US$ 149.8 billion per year.

However, lack of awareness about the usage of bioadhesive microspheres in the treatment of chronic diseases in emerging nations is likely to hinder the growth of bioadhesive microspheres market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global bioadhesive microspheres market are Camurus AB, Henkel Adhesives Technologies India Private Limited, Ashland, Adhesives Research, Inc., The Compound Company BV, EcoSynthetix Inc., Crunchbase Inc. among others.

SEGMENTATION

Among material segmentation, biodegradable synthetic polymers segment is anticipated to hold the largest market share owing to the growing usage of biodegradable synthetic polymers in cancer therapy along with their enhanced drug loading and dose releasing profile at the desired sites.

Key Insights

• Overview of Technological Advancements in Bioadhesive Microspheres Formulations
• Pricing Analysis of Key Products
• The Regulatory Scenario of Key Countries/Regions
• Key Industry Developments - Mergers, Acquisition, and Partnerships

Regional Analysis

The global bioadhesive microspheres market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the market during the forecast period owing to growing awareness and high adoption of novel microspheres used as drug delivery systems. Additionally, growing investments by many key players in the research and development activities are likely to boost the bioadhesive microspheres market during the forecast period. Certain factors such as increase in the prevalence of chronic disease & cancer and growing demand for minimally invasive drug delivery system are some of the factor anticipated to boost the global bioadhesive microspheres market in Asia Pacific region during the forecast period.

Key Industry Developments

• In April 2019, ABK Biomedical Inc., announced about financing $30 million in B series which shall focus on product development of its Eye90 microspheres and Easi-Vue microspheres which are designed for transarterial radiation therapy for liver tumors bland embolic treatment of hypervascular tumors respectively.
• In August 2018, Flexion Therapeutics Inc., received FDA approval for the use of PLA/PLGA-based products as an efficient drug delivery microsphere.